Mass spectrometry in drug development & life science - Technique may reduce costs and minimize risk

被引：0
|
作者：
Fox, S
机构：
来源：
GENETIC ENGINEERING NEWS | 2003年 / 23卷 / 02期
关键词：
D O I：
暂无
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
引用
收藏
页码：12 / +
页数：2
相关论文
共 50 条
  • [41] Development of a High Resolution Mass Spectrometry Method for Urine Drug Screening
    Thoren, K. L.
    Lynch, K. L.
    Shugarts, S. B.
    Wu, A. H. B.
    THERAPEUTIC DRUG MONITORING, 2013, 35 (05) : 663 - 663
  • [42] Editorial: Mass spectrometry-based proteomics in drug discovery and development
    Pejchinovski, Martin
    Magalhaes, Pedro
    Metzger, Jochen
    FRONTIERS IN MEDICINE, 2024, 11
  • [43] Application of accelerator mass spectrometry in drug development - vismodegib as a case study
    Hop, Cornelis
    Graham, Richard
    Wong, Harvey
    Dresser, Mark
    Khojasteh, Cyrus
    Shin, Young
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2015, 250
  • [44] Advanced MALDI mass spectrometry imaging in pharmaceutical research and drug development
    Schulz, Sandra
    Becker, Michael
    Groseclose, M. Reid
    Schadt, Simone
    Hopf, Carsten
    CURRENT OPINION IN BIOTECHNOLOGY, 2019, 55 : 51 - 59
  • [45] Mass spectrometry-driven drug discovery for development of herbal medicine
    Zhang, Aihua
    Sun, Hui
    Wang, Xijun
    MASS SPECTROMETRY REVIEWS, 2018, 37 (03) : 307 - 320
  • [46] Liquid chromatography-mass spectrometry in peptide drug discovery and development
    John, H
    ANALYTICAL AND BIOANALYTICAL CHEMISTRY, 2005, 381 (01) : 51 - 53
  • [47] Development of rapid methodologies for the isolation and quantitation of drug metabolites by differential mobility spectrometry - mass spectrometry
    Hall, Adam B.
    Coy, Stephen L.
    Nazarov, Erkinjon
    Vouros, Paul
    INTERNATIONAL JOURNAL FOR ION MOBILITY SPECTROMETRY, 2012, 15 (03) : 151 - 156
  • [48] Minimize exposure to antidopaminergic drugs whenever possible to reduce the risk of drug-induced parkinsonism and tardive dyskinesia
    Writers, Adis Medical
    DRUGS & THERAPY PERSPECTIVES, 2019, 35 (07) : 326 - 331
  • [49] Minimize exposure to antidopaminergic drugs whenever possible to reduce the risk of drug-induced parkinsonism and tardive dyskinesia
    Drugs & Therapy Perspectives, 2019, 35 : 326 - 331
  • [50] INVESTIGATION OF DIRECT THIN-LAYER CHROMATOGRAPHY MASS SPECTROMETRY AS A DRUG ANALYSIS TECHNIQUE
    DOWN, GJ
    GWYN, SA
    JOURNAL OF CHROMATOGRAPHY, 1975, 103 (01): : 208 - 210
12345